PDF(Pubmed)
Abstract：
BACKGROUND: This study evaluates the efficacy and safety of micropulse transscleral cyclophotocoagulation (MP-CPC) in paediatric patients.
METHODS: This retrospective case-series recruited 44 eyes for glaucoma patients who were younger than 17 years and were treated with MP-CPC and followed for at least one year. Pre- and post-intervention intraocular pressure (IOP) was compared out to at least one year postoperatively. Success rates at 6 months and 1 year postoperatively were assessed. P < 0.05 was considered statistically significant.
RESULTS: There were 35 (79.5%) eyes with a history of glaucoma surgery. IOP decreased statistically significantly from a baseline of 32.7 (standard deviation:8.7 mmHg) to 23.2 (8.6) and 21.7 (7.9) mmHg at the 6 months and 1-year follow-up, respectively (P < 0.0001, all comparisons). Overall success was noted in 19 (47.5%) eyes at the 6 months follow-up, and 23 (53.5%) eyes at 1 year.
CONCLUSIONS: MP-CPC reduces IOP and the burden of medications in paediatric patients with glaucoma. Additionally, its safety profile favours the use of MP-CPC as an adjunctive modality for refractory glaucoma.
METHODS: This retrospective case-series recruited 44 eyes for glaucoma patients who were younger than 17 years and were treated with MP-CPC and followed for at least one year. Pre- and post-intervention intraocular pressure (IOP) was compared out to at least one year postoperatively. Success rates at 6 months and 1 year postoperatively were assessed. P < 0.05 was considered statistically significant.
RESULTS: There were 35 (79.5%) eyes with a history of glaucoma surgery. IOP decreased statistically significantly from a baseline of 32.7 (standard deviation:8.7 mmHg) to 23.2 (8.6) and 21.7 (7.9) mmHg at the 6 months and 1-year follow-up, respectively (P < 0.0001, all comparisons). Overall success was noted in 19 (47.5%) eyes at the 6 months follow-up, and 23 (53.5%) eyes at 1 year.
CONCLUSIONS: MP-CPC reduces IOP and the burden of medications in paediatric patients with glaucoma. Additionally, its safety profile favours the use of MP-CPC as an adjunctive modality for refractory glaucoma.
摘要：
背景：这项研究评估了微脉冲经巩膜睫状体光凝（MP-CPC）在儿科患者中的疗效和安全性。
方法：该回顾性病例系列招募了44只年龄小于17岁的青光眼患者的眼睛，并接受了MP-CPC治疗，随访至少一年。将干预前后的眼内压（IOP）与术后至少一年进行比较。评估术后6个月和1年的成功率。P<0.05被认为具有统计学意义。
结果：有青光眼手术史的35只（79.5%）眼。在6个月和1年随访时，眼压从基线32.7（标准差：8.7mmHg）下降到23.2（8.6）和21.7（7.9）mmHg，分别（P<0.0001，所有比较）。在6个月的随访中，19只眼睛（47.5％）总体成功。1年时23只（53.5%）眼。
结论：MP-CPC可降低小儿青光眼患者的眼压和药物负担。此外,其安全性有利于MP-CPC作为难治性青光眼的辅助治疗方式.
方法：该回顾性病例系列招募了44只年龄小于17岁的青光眼患者的眼睛，并接受了MP-CPC治疗，随访至少一年。将干预前后的眼内压（IOP）与术后至少一年进行比较。评估术后6个月和1年的成功率。P<0.05被认为具有统计学意义。
结果：有青光眼手术史的35只（79.5%）眼。在6个月和1年随访时，眼压从基线32.7（标准差：8.7mmHg）下降到23.2（8.6）和21.7（7.9）mmHg，分别（P<0.0001，所有比较）。在6个月的随访中，19只眼睛（47.5％）总体成功。1年时23只（53.5%）眼。
结论：MP-CPC可降低小儿青光眼患者的眼压和药物负担。此外,其安全性有利于MP-CPC作为难治性青光眼的辅助治疗方式.
